Geode Capital Management, LLC Contrafect Corp Transaction History

Geode Capital Management, LLC

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2022 Feb 13, 2023	SELL	$0.09 - $0.19 $68 - $143	-756 Reduced 0.23%	329,729 $31,000
Q3 2022 Nov 14, 2022	BUY	$0.18 - $3.51 $2,118 - $41,305	11,768 Added 3.69%	330,485 $55,000
Q2 2022 Aug 12, 2022	BUY	$2.79 - $4.45 $26,217 - $41,816	9,397 Added 3.04%	318,717 $978,000
Q4 2021 Feb 11, 2022	BUY	$2.47 - $4.14 $41,360 - $69,324	16,745 Added 5.72%	309,320 $813,000
Q3 2021 Nov 12, 2021	BUY	$3.19 - $4.43 $304,268 - $422,542	95,382 Added 48.37%	292,575 $1.18 Million
Q2 2021 Aug 13, 2021	SELL	$3.58 - $4.9 $592,973 - $811,611	-165,635 Reduced 45.65%	197,193 $867,000
Q1 2021 May 12, 2021	BUY	$4.46 - $6.68 $135,481 - $202,918	30,377 Added 9.14%	362,828 $1.74 Million
Q4 2020 Feb 12, 2021	BUY	$5.05 - $6.4 $12,170 - $15,424	2,410 Added 0.73%	332,451 $1.68 Million
Q3 2020 Nov 13, 2020	BUY	$5.05 - $6.99 $420,422 - $581,931	83,252 Added 33.73%	330,041 $1.74 Million
Q2 2020 Aug 13, 2020	BUY	$4.69 - $7.81 $667,082 - $1.11 Million	142,235 Added 136.04%	246,789 $1.58 Million
Q1 2020 May 14, 2020	BUY	$5.5 - $12.3 $575,047 - $1.29 Million	104,554 New	104,554 $602,000

49.2K

Ticker CFRX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 39,332,700
Market Cap $1.18M
Description
ContraFect Corporation, a clinical-stage biotechnology company, discovers and develops therapeutic protein and antibody products for the treatment of life-threatening and drug-resistant infectious diseases in the United States. Its lead program includes Exebacase, a lysin, which is in Phase III clinical trials for the treatment of staphylococcus...

Get notified when there are updates to the investment portfolio of Geode Capital Management, LLC, based on Form 13F filings with the SEC.

Stay updated on Geode Capital Management, LLC with notifications on news.